



Figure S1. Kaplan-Meier curves for overall survival time for male.


(a)




(b)



(c)




(d)




non-R	43
RD	11
non-R	21
RD	6
non-R	5
RD	3
non-R	2
RD	1

Figure S2. Kaplan-Meier curves for overall survival time for female.


(a)




(b)



(c)



(d)




	non-R	RD
no	4	3
yes	4	2


	non-R	RD
non-RD	6	1
RD	5	1

Figure S3. Intra-observer validations.

(a)



(b)



(c)




Table S1. The prevalence of patients with RD of Δ L3SMI, Δ SFMI, and Δ VFMI between sarcopenia and non-sarcopenia groups.

Variables	Non-Sarcopenia (n=36)	Sarcopenia (n=25)	<i>p</i> value
RD group in Δ L3SMI	7/36	5/25	>0.999
RD group in Δ SFMI	6/36	6/25	0.526
RD group in Δ L3VFMI	10/36	2/25	0.099